Literature DB >> 18478277

Development of a score that predicts survival among patients with bone metastasis revealing solid tumor.

Nicolas Penel1, Antoine Hollebecque, Carlos Maynou, Jérôme Dewaele, Marie Jasserand, Régis Beuscart, Marie-Hélène Vieillard.   

Abstract

BACKGROUND: Bone metastases revealing solid tumors require a multidisciplinary treatment that may include aggressive surgery. Nevertheless, decision making is very difficult because of lack of reliable guidance for life expectancy. Therefore, we had conducted a retrospective study to analyze prognostic factors in this vulnerable population.
MATERIALS AND METHODS: We reviewed the medical charts of 119 consecutive patients with solid tumors treated between August 1999 and December 2007. Survival was estimated using Kaplan-Meier method. Prognostic factors were assessed with Log-rank test and Cox model. There were 77 men and 42 women. RESULTS AND DISCUSSION: The median age was 57 (range, 29-84). The most frequent primaries were lung (51 cases), unknown primary (42 cases), and breast (six cases). The median overall survival was 118 days (1-2,815). Six independent prognostic factors were identified by multivariate analysis: Karnosky index < 80% (HR = 1.92), albuminemia < 38 g/l (HR = 2.60), natremia < 135 mEq/l (HR = 2.78), platelet count > 500,000/mm(3) (HR = 2.71), cutaneous metastasis (HR = 4.6), and pleural metastasis (HR = 4.76). For example, patients with < or =2 of these prognostic factors experienced a median overall survival of 196 days (1-2,875) and their risk of death within the 90 days was 15/77. On the contrary, the patients with more than two poor prognostic factors experienced a median overall survival of about 80 days (1-834) and their risk of early death was 22/32. We had proposed an easily obtained at bedside score that needs further validation on independent cohort.

Entities:  

Mesh:

Year:  2008        PMID: 18478277     DOI: 10.1007/s00520-008-0455-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  22 in total

1.  Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.

Authors:  Gaoping Chen; Kanishka Sircar; Armen Aprikian; Anil Potti; David Goltzman; Shafaat A Rabbani
Journal:  Cancer       Date:  2006-07-15       Impact factor: 6.860

2.  Vertebral metastases: a critical appreciation of the preoperative prognostic tokuhashi score in a series of 71 cases.

Authors:  E A Enkaoua; L Doursounian; G Chatellier; F Mabesoone; T Aimard; G Saillant
Journal:  Spine (Phila Pa 1976)       Date:  1997-10-01       Impact factor: 3.468

3.  Prognostic factors among cancer patients with good performance status screened for phase I trials.

Authors:  Nicolas Penel; Marie Vanseymortier; Marie-Edith Bonneterre; Stéphanie Clisant; Eric Dansin; Yvette Vendel; Régis Beuscart; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2007-09-22       Impact factor: 3.850

4.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.

Authors:  Bradley M Augustson; Gulnaz Begum; Janet A Dunn; Nicola J Barth; Faith Davies; Gareth Morgan; Judith Behrens; Alastair Smith; J Anthony Child; Mark T Drayson
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

5.  The threshold approach to clinical decision making.

Authors:  S G Pauker; J P Kassirer
Journal:  N Engl J Med       Date:  1980-05-15       Impact factor: 91.245

6.  CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.

Authors:  Christophe Borg; Isabelle Ray-Coquard; Irene Philip; Gilles Clapisson; Nathalie Bendriss-Vermare; Christine Menetrier-Caux; Catherine Sebban; Pierre Biron; Jean-Yves Blay
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

Review 7.  Matrix metalloproteinases and metastatic cancer.

Authors:  M I Cockett; G Murphy; M L Birch; J P O'Connell; T Crabbe; A T Millican; I R Hart; A J Docherty
Journal:  Biochem Soc Symp       Date:  1998

8.  Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy.

Authors:  B T Rougraff; J S Kneisl; M A Simon
Journal:  J Bone Joint Surg Am       Date:  1993-09       Impact factor: 5.284

Review 9.  Role of endothelin-1 in osteoblastic bone metastases.

Authors:  Theresa A Guise; Juan Juan Yin; Khalid S Mohammad
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

10.  Metastatic bone disease from occult carcinoma: a profile.

Authors:  M Nottebaert; G U Exner; A R von Hochstetter; A Schreiber
Journal:  Int Orthop       Date:  1989       Impact factor: 3.075

View more
  1 in total

Review 1.  Predictors of Mortality in Patients with Advanced Cancer-A Systematic Review and Meta-Analysis.

Authors:  Catherine Owusuaa; Simone A Dijkland; Daan Nieboer; Agnes van der Heide; Carin C D van der Rijt
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.